Roivant aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter
Joined November 2014
- Tweets278
- Following122
- Followers2.3K
- Likes300
Pinned Tweet
Didn't catch our #JPM26 presentation? Catch the video we presented here
"Either you were in the M&A basket and public markets investors thought you were going to get bought by Big Pharma and your stock traded well, or you weren't...[but] it's great to be in an environment where we have another path forward as a business"
Roivant CEO @gline and @statnews @adamfeuerstein today at #STATSummit. See what Matt had to say on working in biotech, @DarioAmodei, and wood chippers...
If you care about biotech and drug development watch this interview with Matt Gline, the CEO of Roivant, a biotech firm that is now worth $24 billion.
He talks about why he thinks predictions about AI from people like Anthropic’s Dario Amodei are overly optimistic.
“If Dario is right and I'm wrong, and he cures every disease in five years, man, are we all the winners from that outcome,” Gline said.
“I think if you work in this industry, it is very hard not to be skeptical of any of those claims. Because, and I've said this in other settings recently too, biotech is a wood chipper that like is built to like ingest souls and shred them. It's just like such a hard business that like someone comes and they're like, oh, but I've built a computer and I'm going to push a button and all of that goes away and it just works. Like that is probably not the way that's going to go.”
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Full announcement here: investor.roivant.com/news-re…
Roivant's CEO @gline caught up with @BioCentury a few weeks ago -- hear how he is thinking about commercialization, AI, and what's next.
Roivant’s Gline: Evolving from spin-cos to commercial conviction. CEO Matt Gline on upcoming launch, why 10x returns no longer move the needle, and why AI bets haven’t paid off. buff.ly/NuvoFoQ
Off Target Effects conversation with @gline and Joe Edelman is live!
Full episode here: biotechtv.com/post/off-targe…
𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Perceptive Advisors' Joe Edelman discusses with @Roivant CEO @gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm.
Watch the full episode: biotechtv.com/post/off-targe…
What does one of biotech’s most influential investors look for in a company?
In tomorrow’s Off Target Effects episode, @gline talks with Joe Edelman of Perceptive Advisors about the history and evolution of biotech funds, investing through uncertainty, and where the industry goes from here.
Roivant Sciences retweeted
𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Two CEOs who are so unfiltered, even we had to censor them at times. Watch the full discussion with @Roivant CEO @gline and @BridgeBioPharma CEO Neil Kumar on BiotechTV.
Link: biotechtv.com/post/off-targe…
📽️📽️📽️Tune in for an honest, unscripted conversation with @gline and @BridgeBioPharma's CEO Neil Kumar. This was a fun one! Thank you @bradloncar and @BiotechTV + Spotify link below ⬇️
𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: @BridgeBioPharma Founder & CEO Neil Kumar and @Roivant CEO @gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV
Watch the full episode: biotechtv.com/post/off-targe…
We're really excited to share this one with @BridgeBioPharma's CEO Neil Kumar. Was a great discussion -- catch it on @biotechtv tomorrow AM!
𝐃𝐫𝐨𝐩𝐩𝐢𝐧𝐠 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰: In a new episode of Off-Target Effects with @gline, Matt speaks with @BridgeBioPharma CEO Neil Kumar. It will be out tomorrow at 8:00AM ET. Not to be missed!
Don’t miss it — @gline interviews @JMaraganore in the video below. Thanks to @bradloncar and @BiotechTV for the platform!
𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: @JMaraganore has been a champion of innovation throughout his career. He and @gline discuss the road to success at @Alnylam, today's environment, and keeping the U.S. on top.
Watch the episode: biotechtv.com/post/off-targe…
Don’t miss this discussion with @gline and @JMaraganore — going live tomorrow!
𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: Catch a new episode of Off-Target Effects with @gline on BiotechTV. Matt's guest will be @JMaraganore - it is a great discussion that you don't want to miss. Will drop at 8:00AM ET tomorrow!
Until you had this opportunity for companies to "graduate", what it felt like to be a public biopharma CEO...either you were in the M&A basket and public markets investors thought you were going to get bought by Big Pharma and your stock traded well, or you weren't... [but] *it's great to be in an environment where we have another path forward as a business*
Watch the clip from @gline's presentation at #JPM26 #JPM2026
vimeo.com/1153779776?share=c…
Curious about how we’re continuing to evolve at Roivant? Check out the @Biotech2050Pod featuring our CEO, @gline, to learn how we're approaching development: open.spotify.com/episode/2d0…
We had a packed house for our recent Investor Day where we highlighted continued pipeline progress and our outlook for the next phase of growth while maintaining our unique culture, dynamism and focus on shareholder value creation. Review our presentation: investor.roivant.com/static-…
